Equity Details
Price & Market Data
Price: $5.54
Daily Change: -$0.14 / 2.53%
Daily Range: $5.44 - $5.62
Market Cap: $891,303,424
Daily Volume: 1,189,659
Performance Metrics
1 Week: -4.90%
1 Month: -6.37%
3 Months: -3.03%
6 Months: 88.89%
1 Year: 207.3%
YTD: 8.37%
About Annexon, Inc. (ANNX)
Understand the dynamics of Annexon, Inc. (ANNX). The stock is at 5.54, showing a -$0.14 / 2.53% change today. Market cap: 891,303,424. Performance over 1-week (-4.90%) and 3-month (-3.03%) periods are highlighted.
Company Details
Employees: 96
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.